Bristol Myers Squibb raises 2026 revenue and profit outlook

Bristol Myers Squibb Eliquis 2026 forecast Revlimid Opdivo

Bristol Myers Squibb reported second‑quarter 2026 revenue of $12.97 billion, a 6 % year‑over‑year increase, and adjusted earnings of $2.04 per share, topping analyst expectations of $1.59. The company lifted its full‑year 2026 revenue guidance to $49‑$50 billion from the previous $46‑$47.5 billion range and raised its adjusted earnings outlook to $6.75‑$7.00 per share, up from $6.05‑$6.35.

Eliquis sales reached $4.48 billion, up 22 % YoY, prompting an uplift of the drug’s 2026 sales‑growth forecast to 20‑25 % from 10‑15 %. Sales of Revlimid fell 49 % to $425 million, while newer products posted strong numbers: Camzyos $416 million, Reblozyl $735 million, Breyanzi $484 million, and Opdivo $2.49 billion (down 3 %). The company also highlighted progress on its sub‑cutaneous Opdivo version, Qvantig, which generated $261 million in quarterly revenue.

Entities

Accor SA · Adam Lenkowsky · Bristol Myers Squibb · Camzyos · Eliquis · Emeis SA · Euroapi · Guillaume Bouhours · Huvepharma · Inventiva SA · Pierre Boulud · Reblozyl

Claims

What the coverage asserts, and how many sources carry each claim.

[○ 1 SOURCE] Veolia's first‑half 2026 revenue was €22.193 billion, up 0.8% on a comparable basis.
[○ 1 SOURCE] Veolia's EBITDA reached €3.552 billion in H1 2026, a 5% increase.
[○ 1 SOURCE] Accor's RevPAR increased 2.2% year‑on‑year in the first half of 2026. www.webdisclosure.com
[○ 1 SOURCE] Accor's operating profit rose 6.5% to €563 million at constant currency in H1 2026. www.webdisclosure.com
[○ 1 SOURCE] bioMérieux lowered its 2027‑28 organic revenue growth target to 3‑6%, down from 7%. www.lyoncapitale.fr
[○ 1 SOURCE] Emeis reported an occupancy rate of 89.8% in the first half of 2026. brunobertez.com
[○ 1 SOURCE] Inventiva's cash and cash‑equivalents were €166.1 million as of 30 June 2026. www.webdisclosure.com
[○ 1 SOURCE] bioMérieux's operating profit fell 16% year‑on‑year to €313 million in H1 2026. www.lyoncapitale.fr
[● 5 SOURCES] Bristol Myers Squibb raised its full‑year revenue guidance to $49‑$50 billion, from $46‑$47.5 billion. kelo.com · srnnews.com · kfgo.com · wtvbam.com
[● 5 SOURCES] Eliquis sales in the quarter were $4.48 billion, up 22 % year‑on‑year. kelo.com · srnnews.com · kfgo.com · wtvbam.com
[● 5 SOURCES] The company raised its FY‑2026 adjusted earnings guidance to $6.75‑$7.00 per share, up from $6.05‑$6.35. kelo.com · srnnews.com · kfgo.com · wtvbam.com
[● 5 SOURCES] Opdivo sales fell 3 % to $2.49 billion in Q2. kelo.com · srnnews.com · kfgo.com · wtvbam.com